Survival and Recurrence in Vitreoretinal Lymphoma Simulating Uveitis at Presentation: The Possible Role of Combined Chemotherapy

被引：5

作者：

Gozzi, Fabrizio ^{[1
]}

Aldigeri, Raffaella ^{[2
]}

Mastrofilippo, Valentina ^{[1
]}

De Simone, Luca ^{[1
]}

Bolletta, Elena ^{[1
]}

Marzano, Jacopo ^{[3
]}

Iannetta, Danilo ^{[4
]}

Coassin, Marco ^{[5
]}

Ilariucci, Fiorella ^{[6
]}

Ferrari, Angela ^{[6
]}

Luminari, Stefano ^{[6
,7
]}

Merli, Francesco ^{[6
]}

Croci, Stefania ^{[8
]}

Zerbini, Alessandro ^{[8
]}

Farnetti, Enrico ^{[9
]}

Nicoli, Davide ^{[9
]}

Valli, Riccardo ^{[10
]}

Tamagnini, Ione ^{[10
]}

Cavazza, Alberto ^{[10
]}

Salvarani, Carlo ^{[7
,11
]}

Fontana, Luigi ^{[4
]}

Cimino, Luca ^{[1
]}

机构：

[1] Azienda USL IRCCS, Ocular Immunol Unit, Reggio Emilia, Italy

[2] Univ Parma, Dept Med & Surg, Parma, Italy

[3] Univ Sassari, Dept Med Surg & Expt Sci, Sassari, Italy

[4] Azienda USL IRCCS, Ophthalmol Unit, Reggio Emilia, Italy

[5] Univ Campus Biomed Rome, Dept Ophthalmol, Rome, Italy

[6] Azienda USL IRCCS, Hematol Unit, Reggio Emilia, Italy

[7] Univ Modena & Reggio Emilia, Dept Surg Med Dent & Morphol Sci Interest Transpl, Modena, Italy

[8] Azienda USL IRCCS, Clin Immunol Allergy & Adv Biotechnol Unit, Reggio Emilia, Italy

[9] Azienda USL IRCCS, Mol Biol Lab, Reggio Emilia, Italy

[10] Azienda USL IRCCS, Pathol Unit, Reggio Emilia, Italy

[11] Azienda USL IRCCS Reggio Emilia, Rheumatol Unit, Reggio Emilia, Italy

来源：

OCULAR IMMUNOLOGY AND INFLAMMATION | 2022年 / 30卷 / 7-8期

关键词：

Vitreoretinal lymphoma; uveitis masquerade syndrome; CNS involvement; survival; chemotherapy; NERVOUS-SYSTEM LYMPHOMA; PRIMARY INTRAOCULAR LYMPHOMA; HIGH-DOSE METHOTREXATE; CLINICAL-FEATURES; INTRAVITREAL METHOTREXATE; RESPONSE CRITERIA; ASSOCIATION; INFLAMMATION; MANAGEMENT; DIAGNOSIS;

D O I：

10.1080/09273948.2021.1962916

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Purpose: To investigate the role of combined systemic and local chemotherapy in improving the survival of patients with vitreoretinal lymphoma (VRL). Methods: Patients with VRL consecutively seen from 2006 to 2020 were retrospectively reviewed; data on the presence and time of central nervous system (CNS) involvement and treatment regimen (systemic, local or combined chemotherapy) were collected. Overall survival (OS) and progression-free survival (PFS) were calculated for each group. Results: Forty-three eyes of 22 subjects with histology-proven VRL were included. Mean time of survival was 64.8 months (SE +/- 10.8). Twelve patients (57%) presented CNS involvement, which was significantly associated with progression (r = 0.48, P = .03) and death (r = 0.56, P = .009). The isolated primary VRL group had a 5-year OS of 80%. Combined systemic and local chemotherapy reduced the risk of death by 82% (hazard ratio 0.18[0.04- 0.85]) in the entire cohort. Conclusion: Combined systemic and local chemotherapy significantly improved OS but not PFS of patients affected by VRL.

引用

页码：1833 / 1841

页数：9

共 48 条

[1] APRIL and BAFF play a key role in differentiating vitreoretinal lymphoma from uveitis
Tian, Sha
Chen, Kun
Xiao, Jianjiang
Wang, Di
Zhou, Xian
Li, Xiangyu
Shi, Huimin
Li, Yi
Cao, Xia
Guan, Ming
Chen, Bobin
Wang, Qingping
CLINICA CHIMICA ACTA, 2022, 535 : 1 - 6
[2] The Role of Intensive Chemotherapy and Radiotherapy in Plasmablastic Lymphoma: Optimizing Survival Outcomes
Haddad, Philip A.
Lerner, Jaren
Gupta, Ankita
Gupta, Supriya
BLOOD, 2024, 144 : 3084 - 3084
[3] Role of adjuvant chemotherapy on recurrence and survival in patients with resected ampulla of Vater carcinoma
Se Jun Park
Kabsoo Shin
In-Ho Kim
Tae Ho Hong
Younghoon Kim
Myung-ah Lee
World Journal of Gastrointestinal Oncology, 2023, (04) : 677 - 688
[4] Role of adjuvant chemotherapy on recurrence and survival in patients with resected ampulla of Vater carcinoma
Park, Se Jun
Shin, Kabsoo
Kim, In-Ho
Hong, Tae Ho
Kim, Younghoon
Lee, Myung-ah
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 15 (04) : 677 - 688
[5] Combined chemotherapy and radiotherapy improves survival in 1897 testicular Lymphoma patients from a contemporary cohort
Caumont, Fernando
Porter, Christopher
DeBerg, Hannah
Burns, John
Frankel, Jason
Flores, John Paul
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (07)
[6] Survival benefits of patients with non-Hodgkin's lymphoma treated with rituximab combined with chemotherapy.
Shen, ZX
Li, JM
Wang, AH
Chen, Y
BLOOD, 2004, 104 (11) : 240B - 240B
[7] Chemotherapy versus combined chemoradiotherapy: Survival patterns among patients with early stage classical Hodgkin lymphoma
Omar, L. S.
Ali, E. A.
Abd Elbaset, A. K.
ANNALS OF ONCOLOGY, 2018, 29
[8] Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018
Castellino, Alessia
Pulido, Jose S.
Johnston, Patrick B.
Ristow, Kay M.
Bennani, N. Nora
Inwards, David J.
Macon, William R.
Micallef, Ivana N. M.
King, Rebecca L.
Salomao, Diva R.
Witzig, Thomas E.
Habermann, Thomas M.
Nowakowski, Grzegorz S.
AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (03) : 291 - 298
[9] LONG-TERM SURVIVAL AND RECURRENCE-FREE INTERVAL IN COMBINED SURGICAL, RADIOTHERAPY AND CHEMOTHERAPY OF MALIGNANT BRAIN GLIOMAS
MULLER, H
BROCK, M
ERNST, H
CLINICAL NEUROLOGY AND NEUROSURGERY, 1985, 87 (03) : 167 - 171
[10] Role of anemia in survival of patients with elderly aggressive non-Hodgkin's lymphoma after chemotherapy
Zinzani, PL
Tani, M
Alinari, L
Molinari, AL
Stefoni, V
Visani, G
Gentilini, P
Guardigni, L
Fina, M
Baccarani, M
LEUKEMIA & LYMPHOMA, 2005, 46 (10) : 1449 - 1454

← 1 2 3 4 5 →